文献速递中枢神经肿瘤放疗胸部肿瘤放疗

重组人血管内皮抑制素联合全脑放射治疗非小细胞肺癌脑转移患者的疗效与安全性

Efficacy and safety of recombinant human endostatin combined with whole-brain radiation therapy in patients with brain metastases from non-small cell lung cancer.
PubMed 文献 · Radiother Oncol · 2022-07-03

研究将43例非小细胞肺癌脑转移患者随机分为重组人血管内皮抑制素联合全脑放疗组(19例)和单纯全脑放疗组(24例)。联合组中位无进展生存期为8.1个月对4.9个月(p=0.0428),中位颅内无进展生存期为11.6个月对4.8个月(p=0.0437),总生存期为14.2个月对6.4个月(p=0.0688)。联合组脑血容量和脑血流量改善优于放疗组,提示重组人血管内皮抑制素可能改善局部血供和微循环。

要点

  • 联合组中位无进展生存期8.1个月,放疗组4.9个月(p=0.0428)
  • 联合组中位颅内无进展生存期11.6个月,放疗组4.8个月(p=0.0437)
  • 总生存期联合组14.2个月对放疗组6.4个月,p=0.0688未达统计学显著

核心结论

  • 重组人血管内皮抑制素显示出更好的生存获益并改善脑灌注参数,可能为非小细胞肺癌脑转移患者的应用提供进一步见解。

研究设计与样本

  • 共43例脑转移患者随机分为两组:重组人血管内皮抑制素联合全脑放疗组19例,单纯全脑放疗组24例。
  • 主要终点为无进展生存期,次要终点为颅内无进展生存期、总生存期、客观缓解率及脑血容量和脑血流量变化。

主要发现

  • 中位无进展生存期联合组8.1个月 vs 放疗组4.9个月(95%CI 0.2612-0.9583,p=0.0428)。
  • 中位颅内无进展生存期联合组11.6个月 vs 放疗组4.8个月(95%CI 0.2530-0.9504,p=0.0437)。
  • 总生存期联合组14.2个月 vs 放疗组6.4个月(95%CI 0.2508-1.026,p=0.0688),未达统计学显著。
  • 联合组脑血容量和脑血流量改善优于放疗组,提示重组人血管内皮抑制素可能改善局部血供和微循环。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Brain metastasis (BM) is the leading cause of poor prognosis in non-small cell lung cancer (NSCLC) patients. To date, whole-brain radiation therapy (WBRT) is a standard treatment for patients with multiple BMs, while its effectiveness is currently unsatisfactory. This study aimed to investigate the effects of Rh-endostatin combined with WBRT on NSCLC patients with BMs. MATERIALS AND METHODS: A total of 43 patients with BM were randomly divided into two groups. The Rh-endostatin combination group (n = 19) received Rh-endostatin combined with WBRT, and the radiation group (n = 24) received WBRT only. The primary endpoint of the study was progression-free survival (PFS), and the secondary endpoints were intracranial progressionfree survival (iPFS), overall survival (OS), objective response rate (ORR), and changes in the cerebral blood volume (CBV) and cerebral blood flow (CBF). RESULTS: Median PFS (mPFS) was 8.1 months in the Rh-endostatin combination group and 4.9 months in the radiation group (95%CI 0.2612-0.9583, p = 0.0428). Besides, the median iPFS was 11.6 months in the Rh-endostatin combination group and 4.8 months in the radiation group (95%CI 0.2530-0.9504, p = 0.0437). OS was 14.2 months in the Rh-endostatin combination group and 6.4 months in the radiation group (95%CI 0.2508-1.026, p = 0.0688). CBV and CBF in the Rh-endostatin combination group were better improved than that in the radiation group, which indicated that Rh-endostatin might improve local blood supply and microcirculation. CONCLUSION: Rh-endostatin showed better survival and improved cerebral perfusion parameters, which may provide further insights into the application of Rh-endostatin for NSCLC patients with BMs.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Chen L, Tong F, Peng L, et al. Efficacy and safety of recombinant human endostatin combined with whole-brain radiation therapy in patients with brain metastases from non-small cell lung cancer. Radiother Oncol. 2022. PMID: 35788355. doi:10.1016/j.radonc.2022.06.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。